Information Provided By:
Fly News Breaks for November 18, 2015
MYGN, CDNA
Nov 18, 2015 | 09:49 EDT
Mizuho noted that CMS reversed its proposal to cut Medicare pricing for CareDx's (CDNA) AlloMap heart transplant test and will now leave 2016 pricing unchanged at $2,821, which the firm sees as removing a "huge" overhang on the stock. Mizuho also noted that CMS changed its stance on Vectra and will now leave reimbursement as is, which the firm views as a mild positive for Myriad Genetics (MYGN). The firm has a Buy rating on CareDx and a Neutral rating on Myriad.
News For CDNA;MYGN From the Last 2 Days
There are no results for your query CDNA;MYGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.